Non-alcoholic steatohepatitis (NASH) is a subtype of non-alcoholic fatty liver disease (NAFLD) that is characterized by liver cell damage and inflammation (Sheka et al., 2020). NASH is often asymptomatic and is detected incidentally. A liver biopsy is required for diagnosis. NASH can occur with or without liver fibrosis and can progress to more serious liver disease. A total of 20% of NASH patients will develop cirrhosis and all NASH patients are at increased risk for hepatocellular carcinoma (Sheka et al., 2020).
Scope
- Non-alcoholic steatohepatitis report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for NASH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of NASH. The diagnosed prevalent cases of NASH are segmented by age and sex. Additionally, the forecast is further segmented based on fibrosis stage and cirrhosis type. This report also provides the historical and 10-year forecasted total and diagnosed prevalent cases of NAFLD.
Reasons to Buy
The NASH Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global NASH markets.
- Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
- Understand magnitude of the NASH population by age, sex, fibrosis stage, and cirrhosis type.
Table of Contents
- About the Publisher
1 Non-Alcoholic Steatohepatitis: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
